单细胞重建进展轨迹揭示病理性心肌肥厚的干预原则
该研究对小鼠压力超负荷诱导的心肌肥厚进展过程中11,492个单细胞转录组进行分析,刻画心肌细胞与非心肌细胞及其亚型的动态变化和细胞间通讯。研究发现巨噬细胞活化及亚型转换是中期关键事件,达格列净、TD139和Arglabin可靶向该事件保护心功能并减轻纤维化,人类样本中亦观察到类似分子模式。
要点
- 巨噬细胞活化与亚型转换是病理性心肌肥厚中期关键事件。
- 达格列净、TD139和Arglabin可靶向该事件保护心功能并减轻纤维化。
- 人类肥厚型心肌病和心力衰竭样本中观察到类似肥厚分子模式。
核心结论
- 研究揭示了病理性心肌肥厚进展中细胞类型间通讯的动态变化,并提示细胞类型与阶段特异性干预策略。
研究设计与样本
- 基于小鼠压力超负荷诱导心肌肥厚模型,分析不同阶段11,492个单细胞的转录组,鉴定心肌细胞和非心肌细胞主要类型及亚型。
主要发现
- 刻画了心肌细胞、内皮细胞、成纤维细胞和巨噬细胞及其亚型在疾病进展中的动态变化。
- 细胞通讯分析显示心功能恶化过程中特定非心肌细胞呈阶段式利用。
- 巨噬细胞活化及亚型转换是心肌肥厚中期关键事件,达格列净、TD139和Arglabin可靶向该事件保护心功能并减轻纤维化。
- 人类肥厚型心肌病和心力衰竭患者样本中观察到类似的肥厚分子模式。
临床怎么用
- 提示可将巨噬细胞活化及亚型转换作为病理性心肌肥厚中期的干预靶点。
- 达格列净、TD139和Arglabin在动物模型中显示保护心功能并减轻纤维化的潜力,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pressure overload-induced pathological cardiac hypertrophy is a common predecessor of heart failure, the latter of which remains a major cardiovascular disease with increasing incidence and mortality worldwide. Current therapeutics typically involve partially relieving the heart's workload after the onset of heart failure. Thus, more pathogenesis-, stage-, and cell type-specific treatment strategies require refined dissection of the entire progression at the cellular and molecular levels. METHODS: By analyzing the transcriptomes of 11,492 single cells and identifying major cell types, including both cardiomyocytes and noncardiomyocytes, on the basis of their molecular signatures, at different stages during the progression of pressure overload-induced cardiac hypertrophy in a mouse model, we characterized the spatiotemporal interplay among cell types, and tested potential pharmacological treatment strategies to retard its progression in vivo. RESULTS: We illustrated the dynamics of all major cardiac cell types, including cardiomyocytes, endothelial cells, fibroblasts, and macrophages, as well as those of their respective subtypes, during the progression of disease. Cellular crosstalk analysis revealed stagewise utilization of specific noncardiomyocytes during the deterioration of heart function. Specifically, macrophage activation and subtype switching, a key event at middle-stage of cardiac hypertrophy, was successfully targeted by Dapagliflozin, a sodium glucose cotransporter 2 inhibitor, in clinical trials for patients with heart failure, as well as TD139 and Arglabin, two anti-inflammatory agents new to cardiac diseases, to preserve cardiac function and attenuate fibrosis. Similar molecular patterns of hypertrophy were also observed in human patient samples of hypertrophic cardiomyopathy and heart failure. CONCLUSIONS: Together, our study not only illustrated dynamically changing cell type crosstalk during pathological cardiac hypertrophy but also shed light on strategies for cell type- and stage-specific intervention in cardiac diseases.
引用
- Ren Z, Yu P, Li D, et al. Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy. Circulation. 2020. PMID: 32098504. doi:10.1161/CIRCULATIONAHA.119.043053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。